Citations

Showing 10 of 108094 citations.

Estimating mixture effects and cumulative spatial risk over time simultaneously using a Bayesian index low‐rank kriging multiple membership model
Boyle, Joseph , Rothman, Nat, Wheeler, David C. , Boyle, Joseph , Wheeler, David C , Ward, Mary H. , Cerhan, James R.

Mayo Clinic

Statistics in Medicine | September 26, 2022 | Volume: 41 | Issue: 29 | Pages: 5679-5697

10.1002/sim.9587 | PMID 36161724 Get It

The exposome is an ideal in public health research that posits that individuals experience risk for adverse health outcomes from a wide variety of sources over their lifecourse. There have been increases in data collection in the various components of the exposome, but novel statistical methods are needed that capture multiple dimensions of risk at once. We introduce a Bayesian index low‐rank kriging (LRK) multiple membership model (MMM) to simultaneously estimate the health effects of one or more groups of exposures, the relative importance of exposure components, and cumulative spatial risk over time using residential histories. The model employs an MMM to consider all residential locations for subjects weighted by duration and LRK to increase computational efficiency. We demonstrate the performance of the Bayesian index LRK‐MMM through a simulation study, showing that the model accurately and consistently estimates the health effects of one or several group indices and has high power to identify a region of elevated spatial risk due to unmeasured environmental exposures. Finally, we apply our model to data from a multicenter case‐control study of non‐Hodgkin lymphoma (NHL), finding a significant positive association between one index of pesticides and risk for NHL in Iowa. Additionally, we find an area of significantly elevated spatial risk for NHL in Los Angeles. In conclusion, our Bayesian index LRK‐MMM represents a step forward toward bringing the ideals of the exposome into practice for environmental risk analyzes.
Factors Associated With Discrepancy of FFR-Based Lesion Classification Between Intracoronary Bolus and Intravenous Infusion of Adenosine
Kwon, Taek‐Geun , Matsuzawa, Yasushi , Gulati, Rajiv , Lennon, Ryan J. , Lerman, Lilach O. , Lerman, Amir , Lerman, Amir , Lennon, Ryan J.

Mayo Clinic

Journal of Cardiovascular Intervention | September 26, 2022 | Volume: 1 | Issue: 4 | Pages: 158

10.54912/jci.2022.0013 Get It

483. UTILITY OF ENDOLUMINAL FUNCTIONAL LUMEN IMAGING IN DIAGNOSIS OF ESOPHAGEAL DYSFUNCTION FOLLOWING BARIATRIC SURGERY
Yao, Rebecca , Rapaka, Babusai , Dayyeh, Barham Abu

Mayo Clinic

Diseases of the Esophagus | September 26, 2022 | Volume: 35 | Issue: Supplement_2 | Pages: No page available

10.1093/dote/doac051.483 Get It

Abstract We present the case of a 46-year-old male with medically complicated class III obesity who presented with new-onset and persistent dysphagia after undergoing a successful laparoscopic Roux-en-Y gastric bypass surgery. An esophagogastroduodenoscopy was unrevealing, however, further workup with the endoluminal functional lumen imaging probe (EndoFLIP) device was suggestive of esophageal dysmotility with decreased distensibility index of the GE junction and absent/disorganized secondary esophageal peristalsis. Thorough chart review was performed to elicit details of the case presentation. Further, a literature review was performed to supplement background knowledge and discussion. We present a case of symptomatic esophageal dysphagia in a post-procedural bariatric surgery patient with normal EGD yet positive findings on functional lumen imaging, consistent with the newly described entity termed Post Obesity Surgery Esophageal Dysfunction (POSED). POSED is defined by aperistalsis and increased intragastric pressure seen after bariatric surgery. It is thought to occur due to a high-pressure gastric zone created in the noncompliant postoperative stomach after Roux-en-Y gastric bypass, or an increased esophageal afterload by a restrictive laparoscopic sleeve gastrectomy. No treatment guidelines exist, though options include botulinum toxin, dilation, and per-oral esophageal myotomy. This case provides further insight into the role that functional lumen imaging has in the bariatric patient, as it may be able to more accurately detect patients who will develop esophageal dysmotility following bariatric surgery, or perhaps even those who may be predisposed prior to undergoing intervention for weight loss.
Positive Patient Postoperative Outcomes with Pharmacotherapy: A Narrative Review including Perioperative-Specialty Pharmacist Interviews
Parrish, Richard H. , Bodenstab, Heather Monk, Carneal, Dustin, Cassity, Ryan M., Dager, William E. , Hyland, Sara J. , Lovely, Jenna K. , Pollock, Alyssa , Sparkes, Tracy , Wong, Siu-Fun, Parrish, Richard H

Mayo Clinic

Journal of Clinical Medicine | September 26, 2022 | Volume: 11 | Issue: 19 | Pages: 5628

10.3390/jcm11195628 | PMID 36233497 Get It

The influence of pharmacotherapy regimens on surgical patient outcomes is increasingly appreciated in the era of enhanced recovery protocols and institutional focus on reducing postoperative complications. Specifics related to medication selection, dosing, frequency of administration, and duration of therapy are evolving to optimize pharmacotherapeutic regimens for many enhanced recovery protocolized elements. This review provides a summary of recent pharmacotherapeutic strategies, including those configured within electronic health record (EHR) applications and functionalities, that are associated with the minimization of the frequency and severity of postoperative complications (POCs), shortened hospital length of stay (LOS), reduced readmission rates, and cost or revenue impacts. Further, it will highlight preventive pharmacotherapy regimens that are correlated with improved patient preparation, especially those related to surgical site infection (SSI), venous thromboembolism (VTE), nausea and vomiting (PONV), postoperative ileus (POI), and emergence delirium (PoD) as well as less commonly encountered POCs such as acute kidney injury (AKI) and atrial fibrillation (AF). The importance of interprofessional collaboration in all periprocedural phases, focusing on medication management through shared responsibilities for drug therapy outcomes, will be emphasized. Finally, examples of collaborative care through shared mental models of drug stewardship and non-medical practice agreements to improve operative throughput, reduce operative stress, and increase patient satisfaction are illustrated.
Transcranial Magnetic Stimulation during Gait: A Review of Methodological and Technological Challenges
Mate, Kedar K. V., Mate, Kedar , V Mate, Kedar K, Mate, Kedar K V

Mayo Clinic

Neurology India | September 26, 2022 | Volume: 70 | Issue: 4 | Pages: 1448-1453

10.4103/0028-3886.355114 | PMID 36076642 Get It

Abstract Transcranial magnetic stimulation (TMS) is widely used for therapeutic and research purposes such as cognitive studies, treatment of psychiatric disorders, and Parkinson's disease. In research, TMS is perhaps the only technique that can establish a functional connection between brain regions and task performance. In gait research, often TMS is used to identify the extent to which leg motor cortex is involved in different phases on gait cycle. However, using TMS in gait can be challenging for several technical reasons and physiological variations. The objective of this narrative review is to summarize literature in the field of TMS and gait research and present comprehensive challenges. A comprehensive literature search was conducted in PubMed and Google Scholar to identify all relevant literature on TMS and gait. Several critical challenges could potentially impact the findings. For instance, the use of different protocols to obtain motor threshold. This review presents some of the critical challenges in applying TMS during gait. It is important to be aware of these variations and utilize strategies to mitigate some challenges.
Editorial Commentary
Thompson, R. Houston, Parikh, Niki N, Parikh, Niki

Mayo Clinic

Urology Practice | September 25, 2022 | Volume: 9 | Issue: 6 | Pages: 603-603

10.1097/upj.0000000000000341.02 | PMID 37145817 Get It

Functional Testing of Bone Morphogenetic Protein (BMP) Pathway Variants Identified on Whole-Exome Sequencing in a Patient with Delayed-Onset Fibrodysplasia Ossificans Progressiva (FOP) Using ACVR1R206H-Specific Human Cellular and Zebrafish Models
Wentworth, Kelly L. , Lalonde, Robert L. , Groppe, Jay C. , Brewer, Niambi , Moody, Tania , Hansberry, Steven , Taylor, Kimberly E. , Shore, Eileen M. , Pignolo, Robert J. , Yelick, Pamela C. , Pignolo, Robert J , Hsiao, Edward C , Shore, Eileen M , Kaplan, Frederick S. , Hsiao, Edward C.

Mayo Clinic

Journal of Bone and Mineral Research | September 25, 2022 | Volume: 37 | Issue: 11 | Pages: 2058-2076

10.1002/jbmr.4711 | PMID 36153796 Get It

ABSTRACT Bone morphogenetic protein (BMP) signaling is critical in skeletal development. Overactivation can trigger heterotopic ossification (HO) as in fibrodysplasia ossificans progressiva (FOP), a rare, progressive disease of massive HO formation. A small subset of FOP patients harboring the causative ACVR1R206H mutation show strikingly mild or delayed-onset HO, suggesting that genetic variants in the BMP pathway could act as disease modifiers. Whole-exome sequencing of one such patient identified BMPR1AR443C and ACVR2AV173I as candidate modifiers. Molecular modeling predicted significant structural perturbations. Neither variant decreased BMP signaling in ACVR1R206H HEK 293T cells at baseline or after stimulation with BMP4 or activin A (AA), ligands that activate ACVR1R206H signaling. Overexpression of BMPR1AR443C in a Tg(ACVR1-R206Ha) embryonic zebrafish model, in which overactive BMP signaling yields ventralized embryos, did not alter ventralization severity, while ACVR2AV173I exacerbated ventralization. Co-expression of both variants did not affect dorsoventral patterning. In contrast, BMPR1A knockdown in ACVR1R206H HEK cells decreased ligand-stimulated BMP signaling but did not affect dorsoventral patterning in Tg(ACVR1-R206Ha) zebrafish. ACVR2A knockdown decreased only AA-stimulated signaling in ACVR1R206H HEK cells and had no effect in Tg(ACVR1-R206Ha) zebrafish. Co-knockdown in ACVR1R206H HEK cells decreased basal and ligand-stimulated signaling, and co-knockdown/knockout (bmpr1aa/ab; acvr2aa/ab) decreased Tg(ACVR1-R206Ha) zebrafish ventralization phenotypes. Our functional studies showed that knockdown of wild-type BMPR1A and ACVR2A could attenuate ACVR1R206H signaling, particularly in response to AA, and that ACVR2AV173I unexpectedly increased ACVR1R206H-mediated signaling in zebrafish. These studies describe a useful strategy and platform for functionally interrogating potential genes and genetic variants that may impact the BMP signaling pathway. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Characterizing the immune checkpoint marker profiles of cutaneous squamous cell carcinomas in patients with hidradenitis suppurativa
Blum, Franklin R. , Miles, J. Alex , Farag, Sherif W., Johnson, Emma F. , Davis, Mark D.P. , Sayed, Christopher J. , Sayed, Christopher , Hamzavi, Iltefat H. , Lyons, Alexis B. , Googe, Paul B.

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | September 24, 2022 | Volume: 37 | Issue: 3 | Pages: No page available

10.1111/jdv.18598 | PMID 36151986 Get It

Staphylococcus aureus bacteraemia and mortality: a population-based study in Olmsted County, Minnesota, from 2006 to 2020
Hindy, Joya-Rita , Lahr, Brian D. , Baddour, Larry M. , Quintero-Martinez, Juan A , Baddour, Larry , Quintero-Martinez, Juan Andres , DeSimone, Daniel C.

Mayo Clinic

Infectious Diseases | September 24, 2022 | Volume: 55 | Issue: 1 | Pages: 1-8

10.1080/23744235.2022.2123561 | PMID 36151989 Get It

Silmitasertib plus gemcitabine and cisplatin first‐line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study
Borad, Mitesh J. , Bai, Li‐Yuan , Richards, Donald, Mody, Kabir , Rha, Sun Young , Tse, Emmett, O’Brien, Daniel R. , Bayat, Ahmad, Ahn, Daniel H. , Davis, S. Lindsey, Oh, Do‐Youn , Borad, Mitesh J , Hubbard, Joleen M. , Soong, John, McCormick, Daniel, Bayat, Ahmad, Park, Joon Oh

Mayo Clinic

Hepatology | September 24, 2022 | Volume: 77 | Issue: 3 | Pages: 760-773

10.1002/hep.32804 | PMID 36152015 Get It

Background and Aims: This study aimed to investigate safety and efficacy of silmitasertib, an oral small molecule casein kinase 2 inhibitor, plus gemcitabine and cisplatin (G+C) versus G+C in locally advanced/metastatic cholangiocarcinoma. Approach and Results: This work is a Phase 1b/2 study (S4‐13‐001). In Phase 2, patients received silmitasertib 1000 mg twice daily for 10 days with G+C on Days 1 and 8 of a 21‐day cycle. Primary efficacy endpoint was progression‐free survival (PFS) in the modified intent‐to‐treat population (defined as patients who completed at least one cycle of silmitasertib without dose interruption/reduction) from both phases (silmitasertib/G+C n = 55, G+C n = 29). The response was assessed by Response Evaluation Criteria in Solid Tumors v1.1. The median PFS was 11.2 months (95% confidence interval [CI], 7.6, 14.7) versus 5.8 months (95% CI, 3.1, not evaluable [NE]) ( p = 0.0496); 10‐month PFS was 56.1% (95% CI, 38.8%, 70.2%) versus 22.2% (95% CI, 1.8%, 56.7%); and median overall survival was 17.4 months (95% CI, 13.4, 25.7) versus 14.9 months (95% CI, 9.9, NE) with silmitasertib/G+C versus G+C. Overall response rate was 34.0% versus 30.8%; the disease control rate was 86.0% versus 88.5% with silmitasertib/G+C versus G+C. Almost all silmitasertib/G+C (99%) and G+C (93%) patients reported at least one treatment emergent adverse event (TEAE). The most common TEAEs (all grades) with silmitasertib/G+C versus G+C were diarrhea (70% versus 13%), nausea (59% vs. 30%), fatigue (47% vs. 47%), vomiting (39% vs. 7%), and anemia (39% vs. 30%). Twelve patients (10%) discontinued treatment because of TEAEs during the study. Conclusions: Silmitasertib/G+C demonstrated promising preliminary evidence of efficacy for the first‐line treatment of patients with locally advanced/metastatic cholangiocarcinoma.